Voices
Abdul Rahman Jazieh Reviews New FDA Safety Labeling for Capecitabine and 5-FU
Abdul Rahman Jazieh/LinkedIn

Abdul Rahman Jazieh Reviews New FDA Safety Labeling for Capecitabine and 5-FU

Abdul Rahman Jazieh, Chief Executive Officer at Innovative Healthcare Institute, shared a post on X:

“Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency | FDA.”

More posts featuring Abdul Rahman Jazieh on OncoDaily.

 

 

Abdul Rahman Jazieh cancer dihydropyrimidine dehydrogenase (DPD) DPD FDA OncoDaily Oncology